OncologyMerck
Merck Reports Phase 3 KEYNOTE-868 Results for Keytruda in Endometrial Cancer
BMI
Biotechnology Media Insights
Editorial Team · October 8, 2023
Merck announces Phase 3 KEYNOTE-868 trial results showing Keytruda plus chemotherapy significantly improves progression-free survival in advanced endometrial carcinoma.
Merck today announced results from the Phase 3 KEYNOTE-868 trial evaluating Keytruda (pembrolizumab) plus carboplatin and paclitaxel in patients with advanced or recurrent endometrial carcinoma. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with Keytruda.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.